Artemisinin-based combination therapy for ... - The Cochrane Library

D A T A A N D A N A L Y S E S
Comparison 1. Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
63 PCR unadjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Asia 3 1182 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.54, 0.98]
1.2 South America 1 445 Risk Ratio (M-H, Fixed, 95% CI) 6.19 [1.40, 27.35]
2 Total Failure (P. falciparum) Day
63 PCR adjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Asia 3 1062 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.19, 0.79]
2.2 South America 1 435 Risk Ratio (M-H, Fixed, 95% CI) 9.55 [0.52, 176.35]
3 Total Failure (P. falciparum) Day
42 PCR unadjusted
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Asia 5 1969 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.46, 1.69]
4 Total Failure (P. falciparum) Day
42 PCR adjusted
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Asia 5 1898 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.30, 1.39]
5 Total Failure (P. falciparum) Day
28 PCR unadjusted
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Asia 6 2034 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.22, 6.42]
6 Total Failure (P. falciparum) Day
28 PCR adjusted
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Asia 6 2020 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.31, 1.56]
7 P. vivax parasitaemia 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Mixed P. falciparum and
vivax infection at baseline
5 2248 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.12]
7.2 Total P. vivax parasitaemia
by day 28
1 402 Risk Ratio (M-H, Fixed, 95% CI) 7.43 [0.39, 142.89]
7.3 Total P. vivax parasitaemia
by day 42
3 1251 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.11]
7.4 Total P. vivax parasitaemia
by day 63
4 1661 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.91, 1.34]
7.5 P. vivax parasitaemia by
day 63 in those negative at
baseline
3 1172 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.95, 1.56]
7.6 P. vivax parasitaemia by
day 63 in those positive at
baseline
2 79 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.57, 1.65]
8 Gametocyte development (in
those negative at baseline)
3 1234 Risk Ratio (M-H, Fixed, 95% CI) 3.06 [1.13, 8.33]
9 Gametocytaemia carriage 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Gametocyte carriage day 0 2 1174 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.66, 1.73]
9.2 Gametocyte carriage day 7 2 1152 Risk Ratio (M-H, Random, 95% CI) 2.00 [1.54, 2.58]
9.3 Gametocyte carriage day
14
2 1142 Risk Ratio (M-H, Random, 95% CI) 5.14 [3.17, 8.33]
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
109